Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
about
Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and TherapyNovel agents for multiple myeloma to overcome resistance in phase III clinical trialsNew drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Innovative agents in multiple myelomaMaximising the potential of AKT inhibitors as anti-cancer treatmentsRenal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumorsSelective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesotheliomaRevealing the molecular mechanism of gastric cancer marker annexin A4 in cancer cell proliferation using exon arraysAnti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.DC120, a novel AKT inhibitor, preferentially suppresses nasopharyngeal carcinoma cancer stem-like cells by downregulating Sox2.Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance.Cell survival and metastasis regulation by Akt signaling in colorectal cancerAn integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT.Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression.PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.Latest advances and current challenges in the treatment of multiple myeloma.Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value.Bortezomib combination therapy in multiple myeloma.Emerging biological insights and novel treatment strategies in multiple myeloma.Perspectives in the treatment of multiple myeloma.Perifosine--a new option in treatment of acute myeloid leukemia?Future agents and treatment directions in multiple myeloma.Molecularly targeted therapies in multiple myelomaAKT as a therapeutic target in multiple myeloma.Salvage therapy of multiple myeloma: the new generation drugs.Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.Novel agents and new therapeutic approaches for treatment of multiple myeloma.Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine.Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy.Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR‑FGFR1 fusionSignaling Pathways and Emerging Therapies in Multiple Myeloma.
P2860
Q26740191-6556FF51-397C-4AFD-ADF7-CC812A7DDC41Q26822754-DE23EEA0-AC57-46AA-8237-303147E213C9Q27004421-3FFF6BB0-21B3-475E-9422-5A5021B5A320Q27022493-46A788AA-9708-42EF-8B4A-37BDB837C7B9Q28072254-8B50F322-9462-4DE0-ABD1-131F0B3101BAQ30275870-E4408CB1-B7DE-4881-8557-5D88176F6F6AQ33401457-567C0361-E876-41AF-B3B8-EABBFA17B713Q33414827-21CFD08C-FD35-4AE4-82E9-B07BB6247964Q33764664-1B16CF4B-7F54-4574-8FDA-88E231A441BFQ34075096-DB499533-8B98-4AC0-9CBD-A2A1EC8BA204Q34271064-95635FBE-41EF-4A12-9DD2-FF95B13403DEQ34412619-EA8EF556-16AE-44B6-BEA4-3F6FEC2AE04DQ34490880-4F45D32C-6F1E-4800-B50B-B2B671138B5EQ34773850-B926A88F-4F5F-4BD0-8826-8C7B616747B7Q35740115-0C663C56-DC22-4986-AF7A-9A5736216424Q35741309-2FDE0933-21A3-4B03-A8E2-C7F8A177D309Q36736534-76D4E7E0-E61C-45D8-90C2-4A1FF3B2282EQ36938826-5A3B624C-B092-46AF-8F64-DCAFB213CE0DQ37320140-978413F1-6F27-4AA8-9ED9-595EA1B604CEQ37701084-3F25055A-7D0B-4B43-8B03-24243A3C5625Q37717138-945D5241-CB45-42D7-B920-5B230F37BB5BQ37727180-82069735-9D08-4F5D-96B1-C659F55FC120Q37986287-80F8C749-6B8C-43E9-8F82-F6024E7D242BQ38020248-D50C3E94-7D01-4341-BDAC-69DF7BD3AA8BQ38021041-7441B9FB-930C-4B47-954D-70160588F923Q38037600-EDAD1594-BE96-4823-8658-D52EBBDB946AQ38108391-1F170ED0-296E-482C-9C72-4454910E4045Q38127844-1C615079-82A3-4363-9B6A-56E8A4BA01F0Q38172300-C0755113-8239-4C50-B72E-3D98803C1AE1Q38211866-4D6314C3-E29B-4C4A-BDBE-724357CF5D07Q38218256-7BD0D7F7-EA73-4ACE-8385-1A5DD6E14166Q38223433-54860C88-8EE4-4620-927A-5552F014C360Q38242086-349F653F-20F3-4741-AE9F-6B8264A0D350Q38255333-C29E08BE-93ED-4901-8743-EDDA46226172Q38261677-B2D0A3FD-6CCD-4769-BA2D-CA1D52BCC61AQ38474631-A0E1585F-1137-4E5A-A92D-A0E9D9BB198DQ38526844-42833643-3600-4C35-BC8D-5D180ED07309Q38630472-D1AA3303-22D2-4B6D-B9DF-D69FCB2B8821Q38718712-DFAD8C7D-6D26-43E9-A74D-80901FDE1BFEQ38753307-F8FA4B60-16D9-42DD-9FFA-C7EEC4BEBF11
P2860
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Perifosine plus bortezomib and ...... multicenter phase I/II trial.
@en
Perifosine plus bortezomib and ...... multicenter phase I/II trial.
@nl
type
label
Perifosine plus bortezomib and ...... multicenter phase I/II trial.
@en
Perifosine plus bortezomib and ...... multicenter phase I/II trial.
@nl
prefLabel
Perifosine plus bortezomib and ...... multicenter phase I/II trial.
@en
Perifosine plus bortezomib and ...... multicenter phase I/II trial.
@nl
P2093
P50
P921
P356
P1476
Perifosine plus bortezomib and ...... multicenter phase I/II trial.
@en
P2093
Amrita Krishnan
Andrzej Jakubowiak
David Irwin
Enrique Poradosu
Irene M Ghobrial
Jacob Laubach
Jeff Allerton
Jeff Zonder
John Densmore
P304
P356
10.1200/JCO.2010.33.9788
P407
P577
2011-10-11T00:00:00Z